SOURCE: Bovie Medical Corp.

August 27, 2013 08:00 ET

Bovie Medical Corporation Announces J-Plasma® Accepted for Presentation at the Prestigious 42nd AAGL Annual Global Congress on Minimally Invasive Gynecology

MELVILLE, NY--(Marketwired - Aug 27, 2013) - Bovie Medical Corporation (the "Company") (NYSE MKT: BVX), a manufacturer and marketer of electrosurgical products, is pleased to announce that the submission of a video and paper presentation, by noted Gynecological surgeons, Dr. Warren K. Volker and Dr. Melissa Gutierrez, has been accepted for presentation at the AAGL Global Congress to be held in Washington, D.C., November 10-14, 2013. The Congress is attended by several thousand surgeons from around the world, representing highly skilled thought leaders in their respective communities. Jeff Rencher, V.P. of Sales and Marketing for Surgical Products stated: "This acceptance supports Bovie's conviction that J-Plasma® is an innovative surgical tool that can benefit surgeons and their patients in many surgical procedures performed by gynecologists. Furthermore, the presentation should give J-Plasma® worldwide recognition."

Additionally, several other papers are being developed by surgeons in diverse specialties.

About AAGL

The AAGL is the leading association promoting minimally invasive gynecologic surgery among surgeons worldwide. Today, membership extends to over 110 countries and is clearly the recognized authority in minimally invasive gynecology, and includes the foremost authorities in gynecology and pioneers in techniques and procedures.

The presentation and video will be posted on following the final events of AAGL in November 2013.

Cautionary Note on Forward-Looking Statements

Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company's ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company's filings with the Securities and Exchange Commission including the Company's Report on Form 10-K for the year ended December 31, 2012. For forward-looking statements in this new release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

For further information about the Company's current and new products, please refer to the Investor Relations section of Bovie's website

Contact Information

  • For further information contact:
    Bovie Medical Investor Relations and Shareholder Information
    Joseph M. Vazquez III
    Phone: (800) 448-7097